EVM
ANIP icon

Eaton Vance Management’s ANI Pharmaceuticals ANIP Stock Holding History

Eaton Vance Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-503
Closed -$24K – 1847
2021
Q4 		$24K Buy
503
+297
+144% +$12.8K ﹤0.01% 2349
2021
Q3 		$0 Sell
206
-59
-22% -$1.83K ﹤0.01% 2017
2021
Q2 		$9K Buy
265
+217
+452% +$7.38K ﹤0.01% 2550
2021
Q1 		$2K Buy
+48
New +$1.5K ﹤0.01% 2748

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Eaton Vance Management's ANIP Position: Q1 2022 in Review

Eaton Vance Management sold out of ANI Pharmaceuticals (ANIP) in Q1 2022, closing a stake of 503 shares — an estimated $24K sold.

Eaton Vance Management first reported a position in ANIP in Q1 2021 and held it in 4 quarters. The position peaked at $24K in Q4 2021. 126 funds tracked by Wall St. Rank hold ANIP as of Q1 2022.

  • Eaton Vance Management reported no remaining ANI Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 503 ANI Pharmaceuticals shares in Q1 2022, an estimated $24K.
  • Eaton Vance Management first reported a position in ANI Pharmaceuticals in Q1 2021 and held it in 4 quarters.
  • Eaton Vance Management's ANI Pharmaceuticals position peaked at $24K in Q4 2021.
  • 126 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.